Navigation Links
Tarix Orphan Receives FDA Fast Track Designation for TXA127 as Potential Treatment for Duchenne Muscular Dystrophy
Date:10/6/2015

CAMBRIDGE, Mass., Oct. 6, 2015 /PRNewswire/ -- Tarix Orphan LLC, a privately held biopharmaceutical company focused on the treatment of rare neuromuscular disorders and connective tissue diseases, today announced that the U.S. Food and Drug Administration has granted Fast Track Designation to TXA127 (angiotensin 1-7) to reduce skeletal muscle damage and fibrosis and thereby improve muscle strength in Duchenne Muscular Dystrophy (DMD) patients. Tarix Orphan has received notice that clinical testing under the company's Investigational New Drug (IND) application for TXA127 may proceed, and the company expects to initiate a multi-site Phase 2 safety and efficacy study in patients with DMD in early 2016 at both U.S. and European trial sites. Tarix has previously received Orphan Drug Status for TXA127 in the DMD indication in both the United States and Europe.

"Studies with TXA127 have shown significant development potential in preclinical models of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy, and congenital muscular dystrophy, MDC1A and other conditions associated with the TGF-beta pathway. This peptide has several biological actions and has shown positive effects in animals including reductions in muscle fibrosis, increases in muscle strength and ambulation in affected animals, as well as normalization of cardiac dysfunction," said Rick Franklin, Tarix Orphan Chief Executive Officer. "We look forward to beginning our multi-site international Phase 2 study in DMD patients in early 2016. We are additionally preparing a clinical protocol for a study of TXA127 in children with congenital muscular dystrophy (MDC1A), and hope to initiate studies in 2016 in that indication, for which there are no current treatments."

The planned Phase 2 trial will be a double-blind, randomized, placebo-controlled safety and efficacy study of TXA127 in 45 ambulant patients with DMD, conducted for 48 weeks, followed by a 96-week open-label extension study. The study will be conducted at 3 sites in the United States and 3 in Europe. Endpoints for the study will include assessment of muscle quality by MRI, ambulatory assessments including the 2-Minute Walk Test, and safety assessments.

About the U.S. FDA's Fast Track Designation
Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and address unmet medical needs. Companies that receive Fast Track designation are allowed to submit New Drug Applications (NDA) or Biologics License Applications (BLA) on a rolling basis, expediting the FDA review process and benefiting from more frequent communication with the agency to discuss aspects of clinical development. Additionally, drugs that receive Fast Track designation are eligible for accelerated approval and priority review.

About Duchenne Muscular Dystrophy
Duchenne muscular dystrophy (DMD) is a genetic disorder occurring primarily in boys that is characterized by rapidly progressive muscle degeneration and weakness. It is caused by a defective gene for dystrophin, a protein in muscle. Duchenne muscular dystrophy affects approximately 1 in 3500 male births worldwide, with symptoms usually appearing before age 6. Because DMD is an inherited disorder, risks include a family history of Duchenne muscular dystrophy. There is no cure for DMD. Current treatments are aimed at managing the symptoms and slowing the course of the disease.

About TXA127
TXA127 is a pharmaceutical grade formulation of the naturally occurring peptide Angiotensin (1-7) which Tarix Orphan is developing for the treatment of a number of orphan and genetic diseases, with an initial focus on DMD. Additional diseases which may benefit from treatment with TXA127 include congenital muscular dystrophies, Marfan Syndrome, and amyotrophic lateral sclerosis (ALS). TXA127 is part of the "alternative renin angiotensin system (RAS)" and counteracts the "classical" RAS, which promotes hypertension, fibrosis, hypertrophy and inflammation.

About Tarix Orphan
Tarix Orphan LLC is a private biopharmaceutical company focused on the development of TXA127, a pharmaceutical formulation of the naturally occurring peptide Angiotensin (1-7), for the treatment of rare neuromuscular and connective tissue diseases. TXA127 has shown therapeutic activity in animal models of Duchenne muscular dystrophy (DMD), Limb-girdle muscular dystrophy (LGMD), congenital muscular dystrophy (MDC1A), Marfan syndrome, and ALS. Tarix Orphan has broad IP protection for TXA127, and Orphan Drug Designations (ODDs) have been granted for DMD and LGMD in the United States, and for DMD in Europe. For more information on Tarix Orphan, please visit our website at http://www.tarixorphan.com/.

Contact:

Elizabeth Wagner, Vice President
Tarix Orphan
elizabeth.wagner@tarixpharma.com

For Media:

Joan Kureczka
Kureczka/Martin Associates
Joan@kureczka-martin.com
Phone: 415-821-2413

Logo - http://photos.prnewswire.com/prnh/20151005/274091LOGO


'/>"/>
SOURCE Tarix Pharmaceuticals
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Blueprint Medicines Receives FDA Orphan Drug Designation for Novel Drug Candidate for Treatment of Hepatocellular Carcinoma
2. Cloud Pharmaceuticals and THERAMetrics Form Strategic Drug Development Collaboration Targeting Orphan CNS Diseases
3. Rigel Granted Orphan Drug Designation for Fostamatinib in ITP
4. MTG Biotherapeutics Announces that MTG-201 was Granted Orphan Drug Designation by the US FDA for the Treatment of Malignant Mesothelioma
5. Keynote Speakers Announced for NORDs Rare Diseases & Orphan Products Breakthrough Summit
6. Gliknik Licensee Pfizer Receives Orphan Drug Designation From U.S. Food and Drug Administration for Drug Candidate Directed Towards Rare Neurological Disorder
7. HSRx Group In-Licenses Portfolio of Novel Late-Stage Orphan and Breakthrough Combination Drugs, Acquires Ready-for-Market OTC Drugs
8. Biotech Advancements Coupled with Collaborative Partnerships Focus on Developing Orphan Drug Products & Treatments for Critical-Care Patients With Severe Wound Conditions
9. NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer
10. Trigeminal Neuralgia Represents an Attractive Orphan Opportunity in the Pain Field
11. Trigeminusneuralgie ist attraktiv für die Entwicklung eines Orphan-Arzneimittels für die Schmerztherapie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/19/2019)... ... March 19, 2019 , ... Intalere, the healthcare industry ... of its 11th annual Intalere Healthcare Achievement Awards. Through this awards program, Intalere ... and business partners in reducing healthcare costs, improving healthcare quality and serving the ...
(Date:3/18/2019)... , ... March 18, 2019 , ... ... announced today that it has signed an exclusive marketing agreement to sell Simplify ... hospitals and health systems access to one-click-and-done clinical and supply chain documentation for ...
(Date:3/17/2019)... ... 17, 2019 , ... Lofta, Inc., a San Diego based ... agreement with Itamar Medical Ltd. which advances their revolutionary “Complete Path” home sleep ... clinically validated diagnostic tool into their streamlined process. The Itamar Medical WatchPAT is ...
Breaking Medicine Technology:
(Date:3/24/2019)... ... March 24, 2019 , ... Few things are more painful ... prevent tooth pain. Paso Robles dentist , Lisa Lu Davis, has released a ... can help avoid painful conditions. , Pain and soreness from a toothache often radiate ...
(Date:3/23/2019)... ... March 23, 2019 , ... Highway West Vacations has announced its first ... will explore guided mindfulness and hiking in the blooming California desert, learn healthy cooking ... settling in and unwinding next to the Anza-Borrego Desert State Park at Palm Canyon ...
(Date:3/23/2019)... (PRWEB) , ... March 22, 2019 , ... ... Edward Buckingham, M.D. is pleased to introduce the SkinTyte™ laser treatment at Buckingham ... and reconstructive surgeon who recognizes the importance of a beautiful face. Buckingham Center ...
(Date:3/23/2019)... Ariz. (PRWEB) , ... March 22, 2019 , ... ... company providing nutrition and lifestyle solutions, is celebrating 17 years of business and ... in the United States, Puerto Rico, and Canada while supplies last, the meal ...
(Date:3/23/2019)... ... , ... Dr. Srini Pillay , a best-selling author, neuroscientist, tech entrepreneur ... career subverting ideas on creativity and the processes behind human thinking. His recent book ... original release in 2017. Now, the acclaimed doctor has some revealing and worrying thoughts ...
Breaking Medicine News(10 mins):